Raymond James & Associates Novavax Inc Transaction History

Raymond James & Associates

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	BUY	$6.81 - $9.74 $959,998 - $1.37 Million	140,969 New	140,969 $1.02 Million
Q2 2022 Aug 12, 2022	BUY	$36.28 - $75.29 $598,075 - $1.24 Million	16,485 New	16,485 $848,000
Q1 2022 May 11, 2022	SELL	$69.73 - $142.9 $231,643 - $474,713	-3,322 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$134.56 - $217.97 $86,656 - $140,372	-644 Reduced 16.24%	3,322 $475,000
Q3 2021 Nov 02, 2021	SELL	$177.8 - $270.58 $229,717 - $349,589	-1,292 Reduced 24.57%	3,966 $822,000
Q2 2021 Aug 11, 2021	SELL	$121.0 - $257.67 $237,160 - $505,033	-1,960 Reduced 27.15%	5,258 $1.12 Million
Q1 2021 May 14, 2021	SELL	$112.98 - $319.93 $128,232 - $363,120	-1,135 Reduced 13.59%	7,218 $1.31 Million
Q4 2020 Feb 12, 2021	SELL	$78.74 - $139.5 $39,842 - $70,587	-506 Reduced 5.71%	8,353 $931,000
Q3 2020 Nov 04, 2020	SELL	$79.44 - $178.51 $254,446 - $571,767	-3,203 Reduced 26.55%	8,859 $960,000
Q2 2020 Jul 28, 2020	SELL	$13.86 - $83.61 $40,609 - $244,977	-2,930 Reduced 19.54%	12,062 $1.01 Million
Q1 2020 Apr 21, 2020	BUY	$3.93 - $16.0 $12,300 - $50,080	3,130 Added 26.39%	14,992 $204,000
Q4 2019 Feb 12, 2020	BUY	$3.69 - $5.22 $43,770 - $61,919	11,862 New	11,862 $47,000

284

84.8M

5.43M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $731M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.